SCHEMBL6136844

SCHEMBL6136844

N=C(N)C1CC1c1c[nH]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136840 1.00
Trifluoroacetic Acid SCHEMBL6704433 0.87 KDM4E (0.30)
SCHEMBL6705040 0.83 FAAH (0.33)
SCHEMBL4773141 0.77 FFAR1 (0.36)
Hydrochloric Acid SCHEMBL3526047 0.76 FFAR1 (0.35)
Trifluoroacetic Acid SCHEMBL6792658 0.74 KDM4E (0.31)
Vuf-5296 SCHEMBL6136537 0.74
Vuf-5296 SCHEMBL8846403 0.74
Vuf-5296 SCHEMBL7784076 0.74
Vuf-5296 SCHEMBL8846552 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794405-B2 Alicyclic imidazoles as H3 agents MERCK & CO., INC. 2004-09-21 US claimed
US-20040029943-A1 Novel alicylic imidazoles as H3 agents MERCK SHARP & DOHME CORP. 2004-02-12 US claimed
US-20020042400-A1 Novel alicyclic imidazoles as H3 agents GLIATECH, INC. 2002-04-11 US claimed
EP-1313470-A4 NOVEL ALICYCLIC IMIDAZOLES AS H 3 AGENTS GLIATECH INC (US) 2005-02-16 EP disclosed
US-6794405-B2 Alicyclic imidazoles as H3 agents MERCK & CO., INC. 2004-09-21 US disclosed
US-20040029943-A1 Novel alicylic imidazoles as H3 agents MERCK SHARP & DOHME CORP. 2004-02-12 US disclosed
EP-1313470-A1 NOVEL ALICYCLIC IMIDAZOLES AS H 3 AGENTS GLIATECH, INC. (US) 2003-05-28 EP disclosed
US-20020042400-A1 Novel alicyclic imidazoles as H3 agents GLIATECH, INC. 2002-04-11 US disclosed
WO-2002013821-A1 NOVEL ALICYCLIC IMIDAZOLES AS H3 AGENTS GLIATECH, INC. (US) 2002-02-21 WO disclosed